COMP <GO>
SYRE vs ELAN // ALTMAN Z-SCORE & DEBT/EQUITY
Spyre Therapeutics Inc. (NASDAQ) VS. Elanco Animal Health Incorporated (NYSE) • 15-METRIC TALLY: SYRE 3
— ELAN 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SYRE
LAST: $95.51 (-1.09%) • MKT CAP: $10.08B
balance-sheet
26.00
LAST: $24.10 (+4.51%) • MKT CAP: $11.52B
balance-sheet
1.24
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. ELAN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | ELAN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 55.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | -2.50% | -17.50 | ELAN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | 2.45% | -4.09 | ELAN | /fcf-yield <GO> |
| Operating Margin | — | -6.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -4.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 6.20% | +11.40 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 1.24 | +24.76 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ELAN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 51.9 | +5.40 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.96 | -0.07 | ELAN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 20.0x | +2.00 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.08B | $11.52B | -$1.44B | ELAN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | ELAN REV | SYRE GROSS % | ELAN GROSS % | SYRE FCF | ELAN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $586.8M | $4.71B | — | 55.0% | -$169.3M | $284.0M |
| FY 2024 | $584.0M | $4.44B | — | 54.9% | -$157.4M | $394.0M |
| FY 2023 | $886.0K | $4.42B | — | — | -$99.9M | $72.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
ELAN // BETA 0.96